Probiodrug sammelt durch den erfolgreichen Börsengang an der Amsterdamer Börse Euronext 22,5 Mio. Euro ein
5th Biannual NUBIN Symposium on Biomarkers in Neurodegenerative Diseases
HALLE/SAALE, Germany, October 29, 2014 – Probiodrug AG (“Probiodrug”), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces it is the Silver sponsor of the 5th Biannual NUBIN Symposium on Biomarkers in Neurodegenerative Disease taking place on October 29th and 30th in Amsterdam.
The Neuro Unit Biomarkers for Inflammation and Neurodegeneration (NUBIN) symposium, organized by the VU University Medical Center (VUmc) and NeuroCampus Amsterdam (NCA), a world leading neuroscience center in Amsterdam, brings together leading clinicians specializing in neuroinflammatory and neurodegenerative diseases such as Alzheimer’s Disease and Multiple Sclerosis, who will highlight important topics on biomarker research today. This year, the following three topics have been selected: ‘New technologies & new biomarkers’, ‘Blood based biomarkers’ and ‘Biomarkers as surrogate outcome measures’.
Dr Inge Lues, Chief Development Officer of Probiodrug said; “The Alzheimer’s Center at the VUmc is among the world leaders in Alzheimer’s research. As Silver Sponsors of the event, Probiodrug is proud to be part of this renowned Symposium that brings together experts from around the globe with a common goal to identify new diagnostic and therapeutic biomarkers for Alzheimer’s Disease.”
The agenda for the 5th Biannual Symposium can be found here.
In January 2014, Probiodrug and the VUmc Alzheimer Center started a collaboration to assess newly developed molecular biomarker assays for their diagnostic, pharmacodynamic, and therapeutic potential. The assays are designed to detect the presence and concentration of pyroglutamated amyloid beta (pGlu-Abeta), a highly toxic peptide produced by the enzyme glutaminyl cyclase (QC). PGlu-Abeta has been correlated with cognitive decline in individuals with Alzheimer’s Disease and this collaboration seeks to correlate pGlu Abeta concentrations in cerebrospinal fluid (CSF) with disease stage.
For more information please contact:
Dr. Konrad Glund, CEO, Probiodrug Hume Brophy
Email: firstname.lastname@example.org Tel: +44 (203) 440-5653
Notes to Editors:
About Probiodrug AG
Headquartered in Halle, Germany, Probiodrug AG is a biopharmaceutical company focused on the development of new therapeutic products for the treatment of Alzheimer’s Disease.
Founded in 1997, the company successfully developed a novel therapeutic concept for diabetes – the DP4 inhibitors – which provided the basis for a novel class of antidiabetics – the gliptins. Its core capabilities are based on its long-standing expertise in the elucidation of the structure and function of enzymes involved in the modification of proteins and peptides, which play a central role in pathological conditions.
Today Probiodrug’s aim is to become a leading company in the development of Alzheimer’s Disease treatments and to thereby provide a better life for Alzheimer’s Disease patients. It has identified a new therapeutic concept linked to disease initiation and progression. The development approaches are targeting pyroglutamate-Abeta (pGlu-Abeta) as a therapeutic strategy to fight Alzheimer’s Disease. The Company has medical use and composition of matter patents related to the inhibition of QC and anti-pGlu-Abeta- specific monoclonal antibodies, providing it, in the Company’s view, with a leading position in this field of research.
About Alzheimer’s Disease
Alzheimer’s Disease is a neurological disorder, which is the most common form of dementia, and ultimately leads to death. Because Alzheimer’s Disease cannot be cured and is degenerative, the affected patients must increasingly rely on others for assistance. Today, over 35 million people worldwide currently live with the condition and this number is expected to double by 2030 and to more than triple by 2050 to 115 million (World Alzheimer Report 2013).